Parents of preteens across the United States may soon hear new guidance on the human papillomavirus (HPV) vaccine. Researchers are examining data that suggest a single dose might protect against cervical cancer as effectively as the two‑dose regimen currently recommended.
Background on HPV and the vaccine
HPV is the most common sexually transmitted infection in the country, with more than 40 types capable of infecting the genital area, mouth, and throat. The virus is linked to roughly 50,000 cancer cases each year, including about 90% of cervical and anal cancers, according to the Centers for Disease Control and Prevention.
The first HPV vaccine, Merck’s Gardasil, received federal approval in 2006, followed by GSK’s Cervarix in 2009. Both products are authorized for males and females ages 9 through the mid‑20s, but the schedule has focused on 11‑ and 12‑year‑olds because the shots work best before sexual activity begins.
Evolution of dosing recommendations
When the vaccine was introduced, the recommendation called for three doses over six months for girls only. Boys were added to the schedule in 2011. A decade later, in 2016, the dosing was reduced to two shots after studies showed that two doses offered sufficient protection when spaced six to twelve months apart.
Since that change, multiple international studies have documented sharp declines in HPV infections, genital warts, and precancerous cervical lesions. The American Cancer Society also adjusted its cervical‑screening guidelines in 2020, raising the starting age to 25, citing the vaccine’s impact on reducing early‑stage disease.
New research on a single dose
Recent investigations have reignited the conversation about a one‑dose schedule. A large Costa Rican study followed more than 20,000 girls for five years and found that a single shot provided about 97% protection against cervical cancer—comparable to the two‑dose regimen.
Other research, including a review by the University of Minnesota’s Vaccine Integrity Project, continues to show strong protection against a range of HPV‑related cancers in both women and men. A 2024 study published in JAMA Oncology reported that vaccinated males are nearly 50% less likely to develop head‑and‑neck, esophageal, anal, or penile cancers.
Current recommendations and expert views
Despite promising data, the prevailing guidance from the Centers for Disease Control and Prevention and the American Academy of Pediatrics remains a two‑dose series for adolescents. Dr. James Campbell, chair of the AAP’s infectious‑diseases committee, said the organization is actively reviewing the evidence but stresses that “the benefits are very clear. It prevents cancer.”
Dr. Scott Hadland, a pediatrician in Boston, added, “While we await definitive guidance, it’s important that kids receive the full series now to ensure the strongest protection.”
Barriers to vaccination
HPV vaccination rates have lagged behind other adolescent immunizations, with roughly 63% of teenagers receiving both doses for four consecutive years, according to a recent CDC report. The lower uptake is partly attributed to the fact that most states do not require the HPV vaccine for school attendance.
Some parents also cite the vaccine’s sharper sting and brief fainting episodes as concerns. Dr. Hadland noted, “Some of my patients say it hurts more than other shots, but only for a moment.”
Political context
The discussion has taken on a political dimension after the appointment of Robert F. Kennedy Jr. as U.S. health secretary. Kennedy previously led lawsuits against Merck over Gardasil and has publicly questioned the vaccine’s safety, claims that health experts have repeatedly refuted.
In January, Kennedy issued an order to reduce the recommended HPV dose count to one, a move that was blocked by a federal judge. The episode underscores the ongoing tension between scientific consensus and partisan policy proposals.
What parents should do now
Until official guidance changes, health professionals advise parents to follow the current two‑dose schedule. Completing the series provides robust, long‑lasting protection against multiple cancers, a benefit that aligns with the values of protecting families and safeguarding the health of the next generation.
Original reporting: Texarkana Gazette — read the source article.
